UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000026882
Receipt number R000030720
Scientific Title Effect of oxygen administration on pulmonary vascular resistance and cardiac index in patients with chronic thromboembolic pulmonary hypertension.
Date of disclosure of the study information 2017/04/10
Last modified on 2021/12/09 11:36:10

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Effect of oxygen administration on pulmonary vascular resistance and cardiac index in patients with chronic thromboembolic pulmonary hypertension.

Acronym

Effect of oxygen administration on PVR and CI in CTEPH.

Scientific Title

Effect of oxygen administration on pulmonary vascular resistance and cardiac index in patients with chronic thromboembolic pulmonary hypertension.

Scientific Title:Acronym

Effect of oxygen administration on PVR and CI in CTEPH.

Region

Japan


Condition

Condition

chronic thromboembolic pulmonary hypertension.

Classification by specialty

Cardiology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the effect of oxygen administration on pulmonary vascular resistance and cardiac index in patients with chronic thromboembolic pulmonary hypertension.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

Change of pulmonary arterial pressure and pulmonary vascular resistance before and after oxygen administration.

Key secondary outcomes

Change of cardiac index before and after oxygen administration.


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Other

Interventions/Control_1

Oxygen administration

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Patients with chronic thromboembolic pulmonary hypertension whose mean pulmonary arterial pressure is more than 25 mmHg.

Key exclusion criteria

1) Patients with ischemic heart disease.
2) Patients with severe systemic hypertension (systolic blood pressure higher than or equal to 180 mmHg and/or diastolic blood pressure higher than or equal to 110 mmHg).
3) Pregnant patients.
4) Patients with severe valvular heart disease.
5) Patients with a history of acute myocardial infarction and/or cerebral vascular disease within 6 months.
6) Patients with hypotension (systolic blood pressure lower than or equal to 85mmHg).
7) Patients with severe ventricular arrhythmia.
8) Patients with severe renal dysfunction (Serum creatinine higher than or equal to 2mg/dl).
9) Patients with severe liver dysfunction.
10) Patients with chronic inflammatory disease.
11) Patients with malignancy.
12) Patients who were considered as inadequate for enrollment by the principal investigator.

Target sample size

100


Research contact person

Name of lead principal investigator

1st name Hiromi
Middle name
Last name Matsubara

Organization

National Hospital Organization Okayama Medical Center

Division name

Department of Cardiology and Clinical Science

Zip code

7011192

Address

1711-1 Tamasu, Kita-ku, Okayama, Okayama, JAPAN

TEL

086-294-9911

Email

himatsu@okayamamc.jp


Public contact

Name of contact person

1st name Masataka
Middle name
Last name Shigetoshi

Organization

National Hospital Organization Okayama Medical Center

Division name

Department of Cardiology

Zip code

7011192

Address

1711-1 Tamasu, Kita-ku, Okayama, Okayama, JAPAN

TEL

086-294-9911

Homepage URL


Email

m-shigetoshi@umin.ac.jp


Sponsor or person

Institute

Department of Cardiology, Hospital Organization Okayama Medical Center

Institute

Department

Personal name



Funding Source

Organization

none

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Institutional Review Board of the National Hospital Organization Okayama Medical Center

Address

1711-1 Tamasu, Kita-ku, Okayama, Okayama, JAPAN

Tel

086-294-9911

Email

rinsyou@okayamamc.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2017 Year 04 Month 10 Day


Related information

URL releasing protocol

https://doi.org/10.1016/j.jjcc.2021.09.003

Publication of results

Published


Result

URL related to results and publications

https://doi.org/10.1016/j.jjcc.2021.09.003

Number of participants that the trial has enrolled

52

Results

This study included 52 consecutive patients with CTEPH. Oxygen administration significantly decreased mean PAP by 3.8 mmHg ( p < 0.001) and pulmonary vascular resistance by 0.8 Wood units ( p < 0.001). Multivariate regression analysis identified baseline mean PAP as the only significant predictor of decreased mean PAP under oxygen administration. No significant difference in oxygen effect on mean PAP was found between patients with and without vasodilators.

Results date posted

2021 Year 12 Month 09 Day

Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics

Fifty-two patients [mean age 65.2 years, 41 women (79%)] met the study inclusion criteria. Disease duration, i.e. from symptom onset to study enrollment, was approximately 1.5 years. Twenty-five patients (48%) were in WHO functional class III/IV, and 23 patients (44%) were treated with one or more specific pulmonary vasodilators.

Participant flow

A thermodilution catheter was inserted into the pulmonary artery through the right internal jugular vein or right femoral vein. Right atrial pressure, mean PAP, pulmonary capillary wedge pressure, and mixed venous oxygen saturation were measured, and cardiac output and CI were determined by the thermodilution method at baseline, with the patient breathing ambient air. Subsequently, 5 L/min oxygen, which is our routine dose during BPA procedure, was administered by face mask for at least 10 min, and hemodynamic measurements were repeated.

Adverse events

Exposure to oxygen was well tolerated by patients without any discomfort or adverse events.

Outcome measures

The hemodynamics using right heart catheterization while breathing ambient air and with administration of 5 L/min oxygen for 10 min.

Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Main results already published

Date of protocol fixation

2015 Year 03 Month 27 Day

Date of IRB

2015 Year 03 Month 27 Day

Anticipated trial start date

2015 Year 04 Month 01 Day

Last follow-up date

2017 Year 05 Month 31 Day

Date of closure to data entry

2017 Year 11 Month 30 Day

Date trial data considered complete

2019 Year 05 Month 30 Day

Date analysis concluded

2021 Year 08 Month 22 Day


Other

Other related information



Management information

Registered date

2017 Year 04 Month 05 Day

Last modified on

2021 Year 12 Month 09 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000030720


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name